Table 1

Effect of empagliflozin on renal glucose handling in patients with T2D

BaselineAcuteChronicP1P2
Fasting
 Plasma glucose (mmol · L−1)8.7 ± 1.68.9 ± 1.57.6 ± 1.1NS<0.0001
 CrCl (mL · min−1 · 1.73 m−2)103 ± 2597 ± 2593 ± 23NS0.05
 Glucose filtration rate (µmol · min−1)976 ± 338804 ± 251744 ± 222<0.0001<0.0001
 Glucose excretion rate (µmol · min−1)3 ± 14249 ± 101287 ± 112<0.0001<0.0001
 Renal glucose clearance (mL · min−1)0.3 ± 1.134 ± 1343 ± 15<0.0001<0.0001
 Fractional glucose excretion (%)0.2 ± 1.031 ± 1038 ± 12<0.0001<0.0001
Meal
 Plasma glucose (mmol · L−1)11.0 ± 2.1a9.5 ± 1.5a9.5 ± 1.3a<0.0001<0.0001
 CrCl (mL · min−1 · 1.73 m−2)114 ± 22b111 ± 23a105 ± 22aNS0.007
 Glucose filtration rate (µmol · min−1)1,497 ± 454a1,200 ± 322a1,195 ± 329a<0.0001<0.0001
 Glucose excretion rate (µmol · min−1)33 ± 72a555 ± 165a548 ± 180a<0.0001<0.0001
 Renal glucose clearance (mL· min−1)2.4 ± 4.4a58 ± 15a58 ± 17a<0.0001<0.0001
 Fractional glucose excretion (%)1.8 ± 3.0a46 ± 9a46 ± 11a<0.0001<0.0001
  • Data are mean ± SD. NS, not significant.

  • P1, acute vs. baseline P value; P2, chronic vs. baseline P value (Wilcoxon signed rank test).

  • aP < 0.0001;

  • bP < 0.001, meal vs. fasting (Wilcoxon signed rank test).